Goldline Pharmaceutical Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Goldline Pharmaceutical Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹43
Per ShareLot Size
3000 Shares
Minimum Investment
₹1,29,000
Issue Size
₹11.61 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.13%
QIB Quota
49.65%
NII Quota
15.22%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Goldline Pharmaceutical Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
79.7%
Promoter Holding (Post-Issue)
57.3%
Issue Type
Book Building - SME
ISIN
INE1CLW01015
About the Company
We are engaged in the business of marketing pharmaceutical products under the brand name "Goldline." Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the "Goldline" brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.
Industry Overview
The Indian pharmaceutical industry is the world's 3rd largest by volume of production and plays a significant role globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and one of the largest suppliers of low-cost vaccines in the world. Indian manufacturers account for 60 percent of the vaccine supplies to UNICEF, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette-Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. India has the highest number of United States Food and Drug Administration (USFDA) compliant pharma plants outside of the USA. There are 500 API manufacturers contributing about 8% to the global API Industry. India is the largest supplier of generic medicines, with a 20% share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.
Company History
Goldline Pharmaceutical Limited (the "Issuer" or our "Company") was incorporated on August 02, 2004 as `Goldline Pharmaceutical Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 02, 2004 issued by the Registrar of Companies, Maharashtra at Mumbai. Further, our Company was converted into a public limited company pursuant to a resolution passed by the Shareholders in an extraordinary general meeting held on July 18, 2013 and consequently the name of our Company was changed to `Goldline Pharmaceutical Limited' and a fresh certificate of incorporation dated September 23, 2013 was issued by the Registrar of Companies, Maharashtra at Mumbai. The corporate identity number of our Company is U51397MH2004PLC147806.
Products & Services
- The Company is engaged in the business of marketing pharmaceutical products under the brand name "Goldline."
Growth Strategy
- Operational Efficiency.
- Product Portfolio Expansion.
- Customer Base Expansion.
- Brand Visibility.
- Customer Satisfaction.
- R&D Investment.
- Strategic Partnerships.
- Inventory Management, Warehousing, and Logistics.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of 27,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Goldline Pharmaceutical Limited ("Issuer" or "The" "company") at an issue price of Rs. 43 per equity share (including a share premium of Rs. 33 per equity share) for cash, aggregating to Rs. 11.61 Crores ("Public Issue") out of which 1,38,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating Rs. 0.59 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 25,62,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 43 per equity share for cash, aggregating up to Rs. 11.02 Crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 28.13% and 26.69% respectively of the post-issue paid-up equity share capital of the company. Price Band is Rs. 43 per equity share of face value of Rs. 10/- each. The floor price is 4.3 times of the face value. Bids can be made for a minimum of Two lot and in multiples of 3,000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Experienced promoters and management team with industry knowledge and a track record.
- Asset-light business model and competitive products.
- Scalable Business Model.
- Wide and diverse range of product offerings.
- Strong Supplier and Vendor Relationships.
- Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
- The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
- The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
- There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
- Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.